BIR Research has recently announced a report on Global Autism Spectrum Disorder Market based on the Category Industry. The Autism Spectrum Disorder Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Overview of Global Autism Spectrum Disorder Market:
Autism spectrum disorder is a condition related to brain development that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The disorder also includes limited and repetitive patterns of behavior.
The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Autism Spectrum Disorder market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.
Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Autism Spectrum Disorder costs and an increase in the number of treatment on condition related to brain development.
Product Type Segmentation:
The Autism Spectrum Disorder market have different product type such as Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder and Childhood Disintegrative Disorder. Autism Spectrum Disorder market product type gives treatment on condition related to brain development.
Increasing instances across various sectors such as Hospitals, Clinics and Others are raising the need of treatment on condition related to brain development, thereby raising the demand for Autism Spectrum Disorder market. This help in the profitable growth of the Global Autism Spectrum Disorder market in upcoming year.
Segmentation by Regions:
The Autism Spectrum Disorder market in North America has created treatment on condition related to brain development to help hospitals and clinics in the world. The Autism Spectrum Disorder market consists of the treatment on condition related to brain development. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Autism Spectrum Disorder Market during the forecast year.
Top Leading Key Manufacturers are: Pfizer, SynapDx, Behavior Analysis, Autism Therapeutics, Curemark, Roche Pharmaceuticals, Fraser, Retrophin, AutismSTEP. New product launches and continuous technological innovations are the key strategies adopted by the major players.
Top Industry News:
PFIZER RECEIVES EUROPEAN APPROVAL FOR ONCOLOGY BIOSIMILAR, RUXIENCE (RITUXIMAB) ON April 2, 2020– Pfizer Inc. today announced that the European Commission (EC) has approved RUXIENCE (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera (rituximab), for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), and pemphigus vulgaris (PV).
”The approval of biosimilars such as RUXIENCE is an important development for the treatment of certain cancers and autoimmune conditions,” said Igor Aurer, M.D., Ph.D., Professor of Medicine and Head of Hematology Division, University Hospital Centre Zagreb, Croatia. “It’s a step toward allowing clinicians an additional treatment option which can help improve access for patients in need of this established medicine.”
The EC approval is based on a comprehensive data package which demonstrated biosimilarity of RUXIENCE to the reference product. This includes results from the REFLECTIONS B3281006 clinical comparative study, which evaluated the efficacy, safety and immunogenicity, pharmacokinetics and pharmacodynamics of RUXIENCE and found no clinically meaningful differences in safety or efficacy compared to the reference product in patients with CD20-positive, low tumor burden follicular lymphoma.
“Biosimilars like RUXIENCE exhibit a similar safety and efficacy profile to the originator product and have the potential to improve treatment access while reducing healthcare costs,” said Masum Hossain, regional president, Oncology International Developed Markets at Pfizer. “Building on our ongoing commitment to bring biosimilars to market, we look forward to making RUXIENCE available to patients in the EU in the coming months.”
Biosimilars have been a significant catalyst for change for the healthcare industry over the last decade, with the potential to help create more sustainable healthcare systems. With more than 10 years of global in-market experience and a portfolio which now includes seven approved biosimilar products in Europe, Pfizer is proud to be a leader and at the forefront of this vital healthcare segment. This approval follows the positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) in January 2020. RUXIENCE was recently made available to adult patients in the United States for the treatment of NHL, CLL, GPA and MPA and also launched in Japan in January 2020.
Major Points in Table of Contents:
1 Autism Spectrum Disorder Product Definition
2 Global Autism Spectrum Disorder Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Autism Spectrum Disorder Shipments
2.2 Global Manufacturer Autism Spectrum Disorder Business Revenue
2.3 Global Autism Spectrum Disorder Market Overview
3 Manufacturer Autism Spectrum Disorder Business Introduction
3.1 Pfizer Autism Spectrum Disorder Business Introduction
3.1.1 Pfizer Autism Spectrum Disorder Shipments, Price, Revenue and Gross profit 2020-2024
3.1.2 Pfizer Autism Spectrum Disorder Business Distribution by Region
3.1.3 Pfizer Interview Record
3.1.4 Pfizer Autism Spectrum Disorder Business Profile
3.1.5 Pfizer Autism Spectrum Disorder Product Specification
3.2 SynapDx Autism Spectrum Disorder Business Introduction
3.2.1 SynapDx Autism Spectrum Disorder Shipments, Price, Revenue and Gross profit 2020-2024
3.2.2 SynapDx Autism Spectrum Disorder Business Distribution by Region
3.2.3 Interview Record
3.2.4 SynapDx Autism Spectrum Disorder Business Overview
3.2.5 SynapDx Autism Spectrum Disorder Product Specification
3.3 Behavior Analysis Autism Spectrum Disorder Business Introduction
3.3.1 Behavior Analysis Autism Spectrum Disorder Shipments, Price, Revenue and Gross profit 2020-2024
3.3.2 Behavior Analysis Autism Spectrum Disorder Business Distribution by Region
3.3.3 Interview Record
3.3.4 Behavior Analysis Autism Spectrum Disorder Business Overview
3.3.5 Behavior Analysis Autism Spectrum Disorder Product Specification
3.4 Autism Therapeutics Autism Spectrum Disorder Business Introduction
3.5 CUREMARK Autism Spectrum Disorder Business Introduction
3.6 ROCHE PHARMACEUTICALS Autism Spectrum Disorder Business Introduction